Key Facts

Harm reduction is a cornerstone of UK drug policy and public health strategy. It recognises that some individuals cannot or do not wish to stop using substances, and focuses on minimising associated harms. The approach is endorsed by NICE, PHE/OHID, WHO, and UNAIDS.

Epidemiology and Context

• Approximately 300,000 high-risk drug users in England; not all are in treatment
• Needle and syringe programmes distribute approximately 30 million syringes per year in England
• Hepatitis C prevalence among people who inject drugs (PWID): approximately 50%; declining with increased treatment
• HIV prevalence among PWID in England: approximately 1% (low by international standards — attributed to early NSP implementation)
• Drug-related deaths: record levels (~4,900/year); harm reduction measures are crucial to reducing this toll

Principles

1. Pragmatism: drug use is a reality; focus on reducing harm rather than eliminating use
2. Human rights: drug users deserve access to healthcare and respect
3. Evidence-based: interventions proven to reduce morbidity, mortality, and BBV transmission
4. Hierarchy of goals: death prevention > disease prevention > reducing injecting risk > reducing drug use
5. Non-judgemental engagement: meeting people where they are

Policy Framework

• UK Drug Strategy 2021: "From Harm to Hope" — combines harm reduction with treatment and recovery
• NICE PH52 (2014): Needle and syringe programmes — evidence-based recommendations
• NICE NG225 (2022): Drug misuse prevention and harm reduction
• Dame Carol Black Review (2021): highlighted urgent need for increased investment in drug treatment and harm reduction

Target Populations for Harm Reduction

• People who inject drugs (PWID): highest risk for BBV transmission, overdose, injection-related infections
• People who smoke drugs: crack cocaine, heroin (chasing); lower BBV risk than injecting
• Opioid users not in treatment: at risk of overdose, particularly after tolerance loss
• Alcohol-dependent individuals: street drinkers, homeless populations
• Chemsex populations: MSM using GHB/GBL, crystal meth, mephedrone during sexual activity — risk of BBV, overdose, sexual health consequences
• People in criminal justice settings: prison, probation; high rates of substance use

Assessment for Harm Reduction Interventions

• Injecting risk assessment: sites used, sharing of equipment, knowledge of safer injecting
• BBV risk assessment: sharing history, sexual risk, vaccination status
• Overdose risk assessment: lone use, polydrug use, tolerance changes, recent prison release
• Housing and social circumstances: homelessness significantly increases all drug-related harms
• Mental health: co-morbidity assessment

Red Flags Indicating High-Risk Drug Use

• Groin injecting: risk of DVT, femoral artery damage, abscess
• Sharing injecting equipment: BBV transmission risk
• Using alone: no witness to administer naloxone in overdose
• Recent prison release or detoxification: loss of tolerance → overdose risk
• Polydrug use with opioids: benzodiazepines, alcohol, pregabalin synergistically increase overdose risk
• Pregnancy: neonatal abstinence syndrome, BBV vertical transmission

Bedside

• Injecting risk assessment: standardised assessment of injecting behaviour, equipment sharing, injection sites
• Overdose risk assessment: identify modifiable risk factors
• Hepatitis B vaccination status: check and offer if incomplete
• Expired CO reading: if smoking

Bloods / Point-of-Care Testing

• Dry blood spot (DBS) testing: hepatitis B, hepatitis C, HIV — can be done in community settings (pharmacies, outreach services)
• Hepatitis C antibody and PCR: confirm active infection; direct to treatment
• Hepatitis B surface antigen: identify chronic carriers; vaccinate susceptible individuals
• HIV test: opt-out testing recommended for all PWID
• FibroScan: non-invasive liver fibrosis assessment in hepatitis C-positive individuals

Imaging

• Not routinely part of harm reduction assessment
• Duplex ultrasound: if DVT suspected from groin injection

Special Tests

• Urine drug screen: support clinical assessment and treatment planning
• Sexual health screening: particularly for chemsex populations — STI screen, PrEP assessment for HIV
• Wound swab: if injection site infection; identify causative organism

Needle and Syringe Programmes (NICE PH52)

• Provision of sterile equipment: needles, syringes, filters, spoons, water, citric acid, swabs, tourniquets
• Foil provision: clean foil for smoking drugs — reduces injecting-related harm
• Sharps disposal: safe return and disposal of used equipment
• Advice on safer injecting: rotating injection sites, vein care, avoiding groin and neck injection
• Accessible locations: pharmacies, specialist services, mobile/outreach units, vending machines
• Distribute approximately 30 million syringes/year in England

Take-Home Naloxone

• Prenoxad: pre-filled syringe (5 × 400 mcg doses IM); provided to opioid users, families, and services
• Nyxoid: intranasal spray (1.8 mg per dose); no needle required
• Training: simple instruction on recognition of opioid overdose and naloxone administration
• Target groups: all people using illicit opioids, OST patients, prison leavers, family/carers, hostel staff
• Legal protection: no prosecution for administering naloxone in emergency

Blood-Borne Virus Prevention and Treatment

• Hepatitis B vaccination: accelerated schedule for PWID (0, 7, 21 days + 12-month booster); check seroconversion
• Hepatitis C treatment: direct-acting antivirals (e.g. sofosbuvir/velpatasvir — Epclusa — 12 weeks); >95% SVR; treat and prevent paradigm (NICE TA507)
• HIV PrEP: emtricitabine/tenofovir (Truvada) for HIV-negative PWID and chemsex populations at high risk
• HIV treatment: early ART initiation; undetectable = untransmissible (U=U)

Opioid Substitution Therapy

• Methadone or buprenorphine: reduces overdose risk, injecting, BBV transmission, crime (detailed in OST topic)

Supervised Consumption Rooms

• Legally sanctioned facilities where pre-obtained drugs can be consumed under medical supervision
• Not currently legal in England; pilot approved in Glasgow (2023)
• International evidence: reduces overdose death, BBV transmission, public injecting; does not increase drug use or crime

Managed Alcohol Programmes

• Controlled provision of alcohol (e.g. beer/wine at set intervals) to severely dependent homeless individuals
• Reduces consumption of non-beverage alcohol, emergency presentations, and alcohol-related harm

Referral Criteria

• Community drug and alcohol services: all people using substances harmfully
• Hepatology/BBV services: hepatitis C-positive individuals for DAA treatment
• Sexual health services: chemsex populations, BBV-positive individuals
• Housing and social services: homeless individuals using substances
• Mental health services: co-morbid mental illness (dual diagnosis)

Effectiveness of Harm Reduction

• NSPs: reduce hepatitis C incidence by approximately 50% among PWID; contributed to keeping UK HIV prevalence among PWID at ~1% (vs >30% in countries without NSPs)
• Take-home naloxone: associated with ~36% reduction in opioid overdose mortality at community level
• OST: reduces all-cause mortality by ~50%; reduces heroin use, injecting, and crime
• Hepatitis C treatment: >95% SVR with DAAs; WHO elimination target (80% reduction by 2030) potentially achievable in UK
• Hepatitis B vaccination: effective seroconversion in >80% of PWID completing accelerated schedule

Ongoing Challenges

• Drug-related deaths: continuing to rise despite harm reduction efforts; need for expanded access
• Treatment gaps: only ~50% of opioid users in treatment; significant unmet need
• Homelessness: strong association with drug-related harm; housing-first approaches complement harm reduction
• Stigma: barrier to accessing services; affects quality of healthcare received
• Novel substances: rapidly changing drug market challenges existing harm reduction infrastructure
• Funding: real-terms cuts to drug treatment budgets 2014-2020 (Dame Carol Black Review); investment recovering

Hierarchy of Harm Reduction Goals

Key UK Harm Reduction Policy Documents

Comparison of Harm Reduction Interventions